TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06904261: An Open-label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of 12 Month Treatment With Migalastat in Pediatric Subjects (Aged 2 to < 12 Years) With Fabry Disease and Amenable GLA Variants

Sponsor: Amicus Therapeutics · Phase: PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 20 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$877,560

Rescue Site Savings

+$585,040

Unlock Full NCT06904261 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06904261 Rescue Dossier →